Illumina, Inc., a global leader in next-generation sequencing and array-based technologies, announced a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects with cutting-edge tools and workflows.
Together, the longstanding partners will set the standard for scalable single-cell research and accelerate the development of a 5 billion cell atlas within the next three years.
HR Technology Insights: Indeed Labs Unveils New Skincare Innovations for Gen Alpha
“Disease doesn’t wait, and neither do we – Broad Clinical Labs and Illumina are unlocking the massive opportunities of single-cell sequencing to build a deeper understanding of biology,” said Steve Barnard, Chief Technology Officer at Illumina. “Illumina has set the standard in whole genome sequencing, and now, with Broad’s deep experience and long history of translating complex molecular biology assays into high-throughput, high quality workflows, we’re doing the same with single-cell technology to advance precision health.”
“Supporting the entire -omics ecosystem in building these capabilities enables significantly greater insights into key drivers of disease and more rapid translation of these insights into better precision care,” said Niall Lennon, Chairman of the Board and Chief Scientific Officer at Broad Clinical Labs.
HR Technology Insights: Sonde Health Adds Experts to Advisory Board for Voice AI
“By expanding our partnership to single-cell solutions, we’re making significant strides to understand the roots of disease and close the gap between new biological insights and impact for patients,” said Aziz Al’Khafaji, Director of Molecular R&D at Broad Clinical Labs. “The capabilities we’re building, like combining Perturb-seq with Illumina Single Cell 3′ RNA Prep, will support rapid and consistent data generation like we’ve demonstrated in the whole genome space, giving the research community the ability to create billion-cell atlas studies to make the next discoveries.”
The combination of Illumina’s Single Cell Prep, NovaSeq X Plus platform, 25B flow cell and DRAGEN analysis software creates a seamless end-to-end workflow enabling the high-throughput processing of single-cell samples.
Broad Clinical Labs will use this leading workflow alongside state-of-the-art techniques like Perturb-seq, CRISPR screens, and other cutting-edge applications. Together, these capabilities will help researchers process and analyze unprecedented volumes of single cell reads with unparalleled speed and accuracy to make large-scale functional genomics studies possible and accelerate discovery in areas such as disease modeling and drug development.
HR Technology Insights: Prevounce Health Launches Advanced Primary Care Solution
Source – PR Newswire
To share your insights, please write to us at news@intentamplify.com
